BACKGROUND: Investigate whether changes in vitamin D levels affected erythropoiesis stimulating agent (ESA) requirements in chronic kidney disease (CKD) patients with anemia. METHODS: A retrospective cohort study of nondialysis-dependent patients with CKD of all stages. Patients were anemic and on ESA with at least 2 documented 25-hydroxylated vitamin D (D25) levels drawn 4 months apart. Patients were grouped based on the change in their D25 levels. The primary end point evaluated was absolute change in the ESA doses needed to maintain target hemoglobin levels between 11 and 12 g/dl. RESULTS: A total of 153 patients met the inclusion criteria for analysis. With the exception of the normal-to-low D25 group, patients showed a trend toward lower ESA doses with time. The low-to-normal vitamin D group showed a significant reduction in dose of 24% (1,415 units, p = 0.025). The normal-to-low group, however, showed a 22% increase in dose of 1,270 units (NS). Levels of Ca, PTH, and iron indexes were similar across all groups. CONCLUSION: Our retrospective cohort study demonstrates an ESA sparing effect in patients with vitamin D deficiency after repletion to normal levels. Conversely, there was a trend toward increased ESA requirements in patients who became vitamin D deficient from a previously normal state.
BACKGROUND: Investigate whether changes in vitamin D levels affected erythropoiesis stimulating agent (ESA) requirements in chronic kidney disease (CKD) patients with anemia. METHODS: A retrospective cohort study of nondialysis-dependent patients with CKD of all stages. Patients were anemic and on ESA with at least 2 documented 25-hydroxylatedvitamin D (D25) levels drawn 4 months apart. Patients were grouped based on the change in their D25 levels. The primary end point evaluated was absolute change in the ESA doses needed to maintain target hemoglobin levels between 11 and 12 g/dl. RESULTS: A total of 153 patients met the inclusion criteria for analysis. With the exception of the normal-to-low D25 group, patients showed a trend toward lower ESA doses with time. The low-to-normal vitamin D group showed a significant reduction in dose of 24% (1,415 units, p = 0.025). The normal-to-low group, however, showed a 22% increase in dose of 1,270 units (NS). Levels of Ca, PTH, and iron indexes were similar across all groups. CONCLUSION: Our retrospective cohort study demonstrates an ESA sparing effect in patients with vitamin D deficiency after repletion to normal levels. Conversely, there was a trend toward increased ESA requirements in patients who became vitamin D deficient from a previously normal state.
Authors: Justine Bacchetta; Joshua J Zaritsky; Jessica L Sea; Rene F Chun; Thomas S Lisse; Kathryn Zavala; Anjali Nayak; Katherine Wesseling-Perry; Mark Westerman; Bruce W Hollis; Isidro B Salusky; Martin Hewison Journal: J Am Soc Nephrol Date: 2013-11-07 Impact factor: 10.121
Authors: Meredith A Atkinson; Michal L Melamed; Juhi Kumar; Cindy N Roy; Edgar R Miller; Susan L Furth; Jeffrey J Fadrowski Journal: J Pediatr Date: 2013-10-08 Impact factor: 4.406
Authors: Heidi J Kalkwarf; Michelle R Denburg; C Frederic Strife; Babette S Zemel; Debbie L Foerster; Rachel J Wetzsteon; Mary B Leonard Journal: Kidney Int Date: 2011-12-28 Impact factor: 10.612
Authors: Laura H Mariani; Matthew T White; Justine Shults; Cheryl A M Anderson; Harold I Feldman; Myles Wolf; Peter P Reese; Michelle R Denburg; Raymond R Townsend; Joan C Lo; Anne R Cappola; Dean Carlow; Crystal A Gadegbeku; Susan Steigerwalt; Mary B Leonard Journal: J Ren Nutr Date: 2014-03-07 Impact factor: 3.655
Authors: Luigi Francesco Morrone; Pergiorgio Bolasco; Corrado Camerini; Giuseppe Cianciolo; Adamasco Cupisti; Andrea Galassi; Sandro Mazzaferro; Domenico Russo; Luigi Russo; Mario Cozzolino Journal: J Nephrol Date: 2016-04-09 Impact factor: 3.902
Authors: Kathleen E Altemose; Juhi Kumar; Anthony A Portale; Bradley A Warady; Susan L Furth; Jeffrey J Fadrowski; Meredith A Atkinson Journal: Pediatr Nephrol Date: 2018-07-14 Impact factor: 3.714